Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Sunnybrook Research Institute | OTHER |
| Arrayus Technologies Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Single arm, first-in human feasibility study using the Symphony - MRI guided focused ultrasound system for the treatment of leiomyomas. The study is expected to accrue over 12 months. This study will help determine the feasibility to ablate leiomyomas, as measured by MR thermometry and contrast enhanced imaging. In addition, the study will look at the efficacy and safety of the treatment, as measured by the reduction in fibroid size and reduction in symptom severity score and adverse events. This study will help develop future pivotal trials using the same device.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MR Guided High Intensity Focused Ultrasound | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Symphony MRI guided High Intensity Focused Ultrasound (HIFU) | Device | The use of the MRI-HIFU for the ablation of leiomyomas |
|
| Measure | Description | Time Frame |
|---|---|---|
| The ability to ablate fibroid tissue measured by temperature elevation | Measured by MRI thermometry | 1 year |
| The ability to ablate fibroid tissue indicated by Non-Perfused Volume (NPV) | Measure by contrast enhanced imaging | 1 year |
| Safety of the system measured by collection of adverse events related to potential damage to tissue outside the treatment zone | Safety will be measured by collection of adverse events related to potential damage to tissue outside the treatment zone. | 1 year |
| Safety of the system based on damage to skin measured by collection of adverse events related to potential damage to skin over the treatment volume | Safety will be measured by collection of adverse events related to potential damage to skin over the treatment volume. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment efficacy to reduce fibroid size | Reduction of fibroid volume in milliliters | 1 year |
| Treatment efficacy to reduce fibroid size by NPV | Measured by non-perfused volume in milliliters |
Not provided
Inclusion Criteria:
MR-HFU device accessibility to fibroids that at least 50% of fibroid volume can be treated
Fibroids selected for treatment meet the following criteria
Transformed SSS score >= 40
Pre- or peri-menopausal, as indicated by clinical evaluation
Weight < 140 kg or 310 lbs
Willing and able to attend all study visits
Willing and able to use reliable contraception methods
Uterine size < 24 weeks
Cervical cell assessment by PAP: normal, LOW Grade SIL, Low risk HPV or ASCUS subtypes of cervical tissue
Waist circumference <110cm or 43 inches
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Elizabeth | Sunnybrook Reserach Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sunnybrook Health Sciences Centre | Toronto | Ontario | M4N3M5 | Canada |
Not provided
| ID | Term |
|---|---|
| D007889 | Leiomyoma |
| ID | Term |
|---|---|
| D009379 | Neoplasms, Muscle Tissue |
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Pilot single arm feasibility trial.
Not provided
Not provided
Not provided
Not provided
| 1 year |
| Treatment efficacy to reduce symptom severity by Symptom Severity Scores (SSS) | Change in symptoms to be quantified by Symptom Severity Scores (SSS) derived from Uterine Fibroid Symptom and Quality of Life questionnaire. | 1 year |